Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There might be a nugget of truth buried beneath all the BS in there..
Biel’s tech although revolutionary in some ways is being held back because it is analog technology in a digital world.
Kelly needs to digitize it scale it and distribute it in a way that is downloadable from an app. The loop would be the receiver and the digitized app would be the transmitter.
Pretty sure Kelly could hire a software engineer to put it together. If Kelly doesn’t do it someone else will. Get on it Kelly.
AIMO
BIEL
If artificial intelligence was incorporated into biel gadgets people might be more inclined to buy them. AI could save biel. Management's business and marketing plan has, thus far, been a failure.
So these last two years of sales seems to be the 'norm'??? --- OUCH!
>>>Apparently your repeated posts of the same sh*t day after day after day haven't resulted in any change<<<
Any change? The stock price is at ROCK BOTTOM! How much more change can there be? It cannot go any lower. LOL!
C’mon, this IS fun!
Nah, I think I’ll stay! Great entertainment!
Post of the day.
‘Nuff said
BUY $BIEL$
The spike in 2021 is no mystery
BIEL signed the KT Tape deal in 2020. Q4 of 2020 saw 9500 lbs of the KT Wave shipped to KT.
Q2 of 2021 saw 2 shipments to KT totaling 19,000 lbs of the Wave.
BIEL lived up to their end of the contract, suppling all of the Wave devices that KT ordered.
KT failed to aggressively market the Wave. They priced it $5 higher than ActiPatch, $34.95, and reduced the hours of use from 720 to 250. Existing ActiPatch customers said, 'No Thanks'. KT chose to stay in their comfort zone with the athlete/weekend warrior market when the chronic pain market was many times larger.
"Also notice the drop in sales since 2021. The sales in 2022 and 2023 were less than half of 2021. Not the way an investor wants to see company progress ---- ya think?"
Apparently the mast majority of people that actually own shares don't view the sales of 2021-23 as a catalyst to change their positions. Apparently your repeated posts of the same sh*t day after day after day haven't resulted in any change to that regard. Must be frustrating. Then again, we know you don't have a choice. It's your job.
-Shill
Get the hell out of our space - be gone and stay gone. I pretty much think I speak for everyone here. BYE BYE.
‘Nuff said!!!
BUY $BIEL$
"Here's the numbers for 2023 that they reported. Sorry but annuals are all they report now. I'll give you time to revue and then please tell us where you see the positives."
Umm, my views on the 2023 numbers don't matter. The market's reaction after that report matters and the market has spoken. Almost no volume.
Sorry, I know this a bit over your head. Maybe all that Accounting 101 experience you have isn't serving you well.
Shill.
Also notice the drop in sales since 2021. The sales in 2022 and 2023 were less than half of 2021. Not the way an investor wants to see company progress ---- ya think?
Here's the numbers for 2023 that they reported. Sorry but annuals are all they report now. I'll give you time to revue and then please tell us where you see the positives. Notice another year of RED on the bottom line of the income statement.
Notice the total assets on the balance sheet of $144,000 and the total liabilities of $16,000,000 (that is MILLIONS). That's a little ugly ------- ya think???
https://www.otcmarkets.com/stock/BIEL/financials
"I would like to stay and chat about bielcoin"
Who said anyone remotely wanted to chat about bielcoin? Again, comprehension isn't your strong suit.
I want to chat about someone who purposely directs people to a different stock from this board, besmirches that stock and the company, and enjoys watching people lose money. What type of person purposely directs people to lose money? You aught to know since you are that person.
Care to explain?
"Everyone was boasting about their steadfast long positions, claiming to hold onto their shares tightly, but now that the stock has hit rock bottom, you're saying people have sold and repurchased, shifting the goalposts considerably, aren't you?"
You seem to have serious comprehension issues too. Why don't you go read what I posted again, maybe mouth the words this time?
-"Yes".
I would like to stay and chat about bielcoin, but my shift at Burger King starts in 20 minutes. I have been tapped as crew leader yet again.
Everyone was boasting about their steadfast long positions, claiming to hold onto their shares tightly, but now that the stock has hit rock bottom, you're saying people have sold and repurchased, shifting the goalposts considerably, aren't you?
-Yes
/Banjo50
Re: None
Thursday, April 04, 2024 3:03:32 PM
Post#
328135
of 328372
SELL ALL OF YOUR BIEL AND PUT THE PROFITS INTO TRUMP MEDIA GROUP!!! SYMBOL DJT!!! THE TRAIN IS LEAVING THE STATION!!!/
" No one here wants to talk about other stocks." Care to try again?
Grow up.
No one here wants to talk about other stocks. They want to talk about biel and how to make biel profitable. My idea for bielcoin in nothing short of brilliant. One of the big advantages is that bielcoin sounds like bitcoin. If bielcoin were priced below bitcoin many investors might think they are buying bitcoin at a discount when they are actually buying bielcoin. This would push up the price of bielcoin and the investors could unload at a profit. I would propose that one bielcoin be issued for each share of biel stock. I don't see any other way for biel longs to recover their money unless biel announces that they have incorporated AI into their devices. They don't actually have to have AI in their gadgets they just have to announce it. Once this happens the price might jump up to .0004 cents per share and the biel longs could unload. Everyone comes out a winner.
" Let's talk about bielcoin."
I actually think we should talk about why you have insisted people invest in other companies on this board all while besmirching that other company and the posters on that board?
Remember? In case you forgot and for reference to other readers of this board, it's the stock related to DJT's social media platform.
What type of a person intentionally tries to get people to lose their money all while seemingly enjoying it? People need to really consider taking anything you post seriously. More importantly, they should just disregard anything you post all together. They'd be better off for it.
Exactly, who cares about the financials they're history. Let's talk about bielcoin.
"But no talk about the financials?"
What's there to talk about? Year end 2023 has posted. We don't know Q1 for this year, yet. The market has reacted. Yet you feel the need to post the same sh*t over and over and expect the market to react? Maybe you need to take an Accounting 101 class? The market has read the financials and acted appropriately. You, not so much.
Besides, I've already told you. I don't discuss anything with posters that are as disrespectful and disgusting as you. I just point out your lies and manipulations. Oh, and abhorrent behavior like you claiming Phantom Limb Pain is fake. You still remember that one, right.
Shill.
I would have to say that today's ask slap volume was rather disappointing. It would only take a few hundred million in slaps to get the ask back up to .0003 cents per share. Even so, there seems to be no real appetite for biel shares at any price. Once again, I have to ask where are the loyal longs? Any bagholder, excuse me, shareholder who truly believes in biel should be slapping the ask with vigor. If the longs aren't buying it is because they no longer believe that they can make a profit with this stock!!! The price per share has never been this low!!! It is a bargain!!!
But no talk about the financials? No talk about the continuing yearly NET LOSS again for 2023? Yes, just another year that this company has failed to show a profit in. ---- along with every other year they have been in existence. No talk of how they are going to pay off all those note/loan liabilities that have all matured? Were they extended? At what interest rate? Was that unpaid interest on notes now added to the principle to increase that liability? Maybe so as the note/loan liabilities have increased to over $12 MILLION. No talk about the laughable asset/liability ratio that was reported for 2023? No talk of the 'cash on hand'? No talk about the accumulated deficit?
I didn't think so. Only feeble attempts at mocking those that point out the sad state this company is in.
Did you take that accounting 101 course yet? Maybe THEN you will understand all of the above!
Have a great day! ---- and thanks for the entertainment!
https://www.otcmarkets.com/otcapi/company/financial-report/374761/content
Well, nobody seems to like my bielcoin idea. Well then, how about using artificial intelligence to make biel gadgets work? Management would just have to announce that biel gadgets use AI. They wouldn't actually have AI. Just the announcement would be enough to drive up the price so that the longs could unload their shares.
"Oh NO ---- the floor is yours, please continue ---- very entertaining!"
Another cowardly response from one of the top frauds on this board.
See, you claimed that Phantom Limb Pain is fake and then reveled in that view. I offered you the option to redeem yourself, but you refuse. It's one of the main reasons people find you disgusting and despicable. Yet you expect people to read anything you write to be credible, when the opposite is true.
By all means, "please continue" indeed.
Shill.
"So their goal is to break even"
Your comprehension is about as good as mr. "FUN" guy. Try reading it again. Wow.
Seriously, go sit on that back porch of yours. Get some fresh air and play with your instrument. You might actually accomplish something.
>>>the floor is all yours.<<<
Oh NO ---- the floor is yours, please continue ---- very entertaining!
So their goal is to break even. Not much of an investment strategy. BUT WHAT ABOUT MY BIELCOIN IDEA???
So their goal is to break end. Not much of an investment strategy. BUT WHAT ABOUT MY BIELCOIN IDEA???
"More great entertainment! SELLOFF? It is trading at rock bottom! Seems like the 'sell off' has been going on for quite some time now ---- ya think? Do you want to see more volume? I am sure that many (true longs) who are holding, see selling now at ROCK BOTTOM does no good, as their investment is at ROCK BOTTOM. Might as well HOLD and PRAY that some miracle will occur that will save their investment and raise this from the bottom.
"Pathetic stunt"? -- WOW!"
Yup and reality used to be a fried of yours. What's the bid at today?
Anytime you want to talk about Phantom Limb Pain being fake, the floor is all yours.
Shill.
"PRAY that some miracle will occur that will save their investment and raise this from the bottom." BIELCOIN COULD BE THAT MIRACLE!!!
"That was then and this is now. "
Carbon monoxide is getting pretty high in that double-wide of yours.
You see the problem is the "then" allowed the "now" shareholders to get their initial investment back, some with a profit. It also allowed them to still hold on to many millions of shares that are locked up an not going anywhere. That's why that little stunt on Friday didn't do anything to affect today's trading. Another failure by the keyboard cowboys.
Probably too hard of a concept for you to grasp.
>>>More importantly, is it any wonder the market didn't react today to that pathetic stunt on Friday? Where's the massive sell off?<<<
More great entertainment! SELLOFF? It is trading at rock bottom! Seems like the 'sell off' has been going on for quite some time now ---- ya think? Do you want to see more volume? I am sure that many (true longs) who are holding, see selling now at ROCK BOTTOM does no good, as their investment is at ROCK BOTTOM. Might as well HOLD and PRAY that some miracle will occur that will save their investment and raise this from the hole this company has put their investment in.
"Pathetic stunt"? -- WOW!
That was then and this is now. What about my bielcoin idea??? Is it a good idea or not???
/Capsule
Re: None
Monday, April 22, 2024 2:17:07 PM
Post#
328623
of 328627
Sadly, it seems like every long-term investor is now down over 95% from their initial investment.
Ouch!
-Yes/
What about all of those investors that bought years ago, sold for a profit and now sit on many millions of free shares? Care to explain to them what % they are "down" from their initial investment. There's a lot of them out there and it shows in the market activity.
"Ouch!"
Whatever.
Yes, yes that's all well and good, but what about creating a crypto currency and calling it bielcoin. That would be a sure money maker for biel.
"Is it any wonder that Friday's close was at rock bottom?"
More importantly, is it any wonder the market didn't react today to that pathetic stunt on Friday? Where's the massive sell off? Seems to be plenty on the bid at .0001 today.
While I'm sure you find other posters entertaining, the reciprocal isn't quite the same. I highly doubt I'm going out on a limb to state that most other posters on here find you disgusting and despicable. Still standing behind your statement that Phantom Limb Pain isn't real? Again, disgusting and despicable.
Shill.
What about my idea about bielcoin? I never got any feedback from management. Everyone should e-mail the company and demand that they start bielcoin. It is the ONLY way to save the biel longs.
NOT BOBBY!!! He's only down 50%.
Sadly, it seems like every long-term investor is now down over 95% from their initial investment.
Ouch!
-Yes
But it IS entertaining and you are numero uno who males it entertaining. And also all the 'true longs'. Never talking about the sad financials or the laughable stock price that has plummeted to all time lows. Only making feeble attempts to mock any that post that sad state this company is in. Have you read those financials that the CEO has finally reported? The annual report because she feels it is NOT necessary to keep her loyal stockholders up to date with quarterly reports anymore. Did you notice that once again, they have kept their streak going of NEVER reporting a yearly profit? Yep, over twenty years in business. Did you notice the over $12 MILLION in note/loan liabilities they OWE. Did you notice the laughable asset/liability ratio and the $4000 in cash they have on hand, to pay those liabilities?
Oh well, now we will have to wait until next year for the annual report to see if anything is improving.
Is it any wonder that Friday's close was at rock bottom?
"How about if if you are here for the entertainment? --- ie GO BIEL - GO KELLY"
And yet another cowardly example of a top fraud on this board.
Are you new readers paying attention?
Shill.
"C'MON, where are you going to get entertainment like THIS???"
Another example of one of the top frauds on here cowardly hiding behind the real reason they continue to lie and manipulate on a bottom feeding site.
Shill.
"You're right! Message board opinions mean nothing!"
Au contraire, mon frère. Your opinion that Phantom Limb Pain isn't real has a lot of meaning. Regrettably for you the meaning behind it isn't very good.
It just shows another fraud of an anonymous poster who cowardly hides behind the claim that this is entertaining. You still think disrespecting the military, diabetics, factory workers, skilled trades, and other groups who have lost a limb entertaining?
You're simply one of the top frauds on here that has to be here. You're a paid shill that is kept on a short leash.
The Assisi Loop is the animal version of the Endonovo Sofpulse
They use the same 27.12 MHz signal as the ActiPatch but there are several differences.
Assisi/Sofpulse uses 2 of the 2032 3 volt batteries where the ActiPatch uses one.
Assisi/Sofpulse is said to have an 8 day continuous use life span while ActiPatch has a 30 day continuous use life.
Assisi/Sofpulse is made to deliver therapy in sessions of 15-30 minutes with 2 hour gaps between sessions while the ActiPatch delivers a constant, lower powered therapy.
The pulse rate is all so different between the devices.
/band aid
Re: band aid post# 328586
Sunday, April 21, 2024 11:16:40 AM
Post#
328588
of 328616
Oh and more importantly that silly mouth piece P4P. LOL The keyboard pirate that thinks he knows what someone has invested or not in this turd../
Wow, looks like someone was on a weekend bender. Still claim to have a whole 4 million shares while insisting the company needs to do a RS?
Fraud.
/Lifetime
Re: G-star post# 328571
Sunday, April 21, 2024 10:50:14 AM
Post#
328587
of 328615
Typical OTC conspiracy theories… like MM manipulation, offshore shorting syndicates, and paid bashers.
Like Bigfoot, you hear alot about them but never see it./
https://www.wsj.com/articles/u-s-prosecutors-charge-6-with-running-500-offshore-money-laundering-scheme-1410285363
Let's see, the Wall St. Journal or another fraudulent anonymous poster on a bottom feeding stock message board?
Whatever.
See, I knew you couldn't agree to refrain from posting on my beloved BIEL.
At least refrain from posting grammar mistakes.
"Forget what the P4P HAS TO SAY he is just a typer that wants to be confronted. He has no remorse for the true longs that got fnnnnnnnnnnnnnnnnnnn fleeced here by lies and you name it."
Looks like someone else hit the sauce on Friday. This post is dripping with irony considering this person's posting history shows a complete lack of remorse. I personally hope all longs here make money, hopefully a lot of it. This poster revels in the stock price going down. How does that show remorse for longs? I personally am hopefully of the companies success when I see results as good as the Phantom Limb study and Canine Arthritis study. This person bemoans and berates using derogatory language against the company and management. This person roots for the company to fail, for people to loose their jobs. Again how is that remorseful to the company and by default, longs.
This poster is just another anonymous fraud on here. They claim to buy shares and then days latter call for a RS. Yeah, right.
Whatever.
Whatever.
Followers
|
1057
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
328663
|
Created
|
05/18/05
|
Type
|
Free
|
Moderators misanthrope Capsule JustGoDeep toohot JNdouble1 gimmee greenbacks |
PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) ("the Company") back onto the "Stock Day" podcast. Andy spoke with Everett about their progress in the US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch(R) Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx(R) Devices for chronic and post-operative wound care; Allay(R) Menstrual Pain Therapy. For more information, please visit http://www.bielcorp.com/
The Company is currently pursuing multiple US partnership opportunities that are partially contingent on additional FDA clearance for the treatment of musculoskeletal pain, back pain, knee pain, muscle, hip, carpal tunnel, etc. Whelan said,"Patience is key throughout this process. It's going as well as it can." Additionally, the Company anticipates solidifying deals with two new major distributors in the Asian and Eastern European markets.
The Company's product development and regulatory clearances are going well. Now, with pre-submission clearance, the 510(k) relief of musculoskeletal pain market clearance application will be filed by the end of June.
The US FDA has recently implemented an Innovation Program seeking "Breakthrough Devices" to Prevent and Treat Opioid Use Disorder. Opioids are routinely used for post-operative pain. Our United Kingdom ActiPatch User Registry accounts that 71% of opioid customers report a moderate (50%) to complete (100%) elimination in opioid medication use. The Company plans to submit its post-operative pain relief market clearance application into this program. The FDA's assistance, participation, and approval will provide credence and accelerate product market acceptance.
The Company has begun shipments of its new single box kinesiology tape product to be used for back, knee, hip, and muscles and joints in lieu of the back wrap, knee wrap and muscle and joint adhesives. The kinesiology tape is easier to use, reduces product costs, and retail shelf space requirements.
The Company is transitioning its United Kingdom over-the-counter sales and marketing from the front of the store to behind the counter to expand product availability from a few stores to all 14,000 pharmacies. Most pharmacies obtain daily product deliveries and most people in the UK qualify for free prescriptions.
Whelan is confident in the direction the Company is moving, and cites the unique nature of their products as a factor that helps the Company stand out in the global medical electronics industry. Whelan then said, "This is one busy little Company."
"Stock Day" host Everett Jolly stands by his assessment from his April interview with the company that the stock is very undervalued. BioElectronics Corporation trades on the OTC Pink market under the ticker symbol BIEL. Shares are currently selling at 0.0037, up over 100% since April.
For more details about the Company's recent FDA meetings, potential partnership opportunities, and attempts to combat the ongoing opioid crisis, follow the link below to hear the full interview.
https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-3/ ;
About BioElectronics Corporation
BioElectronics develops and manufactures unique nonprescription affordable neuromodulation medical devices. The Company's technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation for many neurological disorders, and specifically chronic pain. Central sensitization is difficult, if not impossible, to address through pharmacotherapy without having a detrimental impact on normal physiologic function. Moreover, pharmacological and masking therapies (creams, heat patches, TENS etc.) have limited effectiveness for chronic pain due to their transient nature. BioElectronics' electromagnetic stimulation therapy has the distinct advantage of being safe, affordable, long lasting, and effective pain relief.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK […]
FREDERICK, MD, May 29, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com reports that it has cancelled today’s scheduled US Food and Drug Administration meeting. “The FDA’s response to our questions, suggestions, and instructions are more than adequate for us to proceed with filing of the formal 510(k) Market Clearance Application,” stated Ian […]
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what […]
FREDERICK, MD, May 02, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two meetings have been scheduled with the US Food and Drug Administration (FDA) to seek expanded over-the-counter (OTC) clearances for their drug-free, wearable medical devices. The first meeting will take place on May 9th, 2018 to […]
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) — Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) (“the Company”), return to the “Stock Day” podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product […]
FREDERICK, MD, March 19, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. Currently there are 700,000 total knee replacement surgeries in the US alone and are projected to grow 673% to 3.5 million procedures per […]
PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) — The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world […]
FREDERICK, MD, Jan. 09, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today that CARE Pharmacies has committed to introducing ActiPatch, Musculoskeletal Pain Therapy medical device to its patients. “With the current opioid crisis here in the United States, as pharmacists, we […]
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half […]
FREDERICK, MD, Dec. 12, 2017 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain […]
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (BIEL) , www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what regulatory pathway should be followed to get market clearance. The focus of the May 9 pre-submission meeting was in discussing the FDA’s feedback on the clinical outcomes and statistical techniques used in reporting the back-pain study.
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
The company was represented by their clinical R&D team comprising: Sree Koneru, Ph.D., VP Product Development, Ian Rawe, Director Clinical Research of BioElectronics (BIEL), Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D. Professor Duke University. Dr. Koneru, who led the discussion, expressed confidence in the FDA’s constructive feedback. “We are pleased that the FDA viewed our data and statistical methods favorably. They have provided guidance on how to combine the back-pain study results, along with our previously cleared 510(k), into a single 510(k) submission for obtaining expedited expanded market clearance.”, he said.
An additional pre-submission meeting is scheduled with the FDA on May 29th, 2018 to seek expanded indications in a separate application for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
BioElectronics VP of Sales Discusses Pre & Post-operative Pain Relief Surgical Program in "Stock Day" Interview
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) ("the Company"), return to the "Stock Day" podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product opportunity from the recent National Health Service payment approval for its ActiPatch® medical device.
BioElectronics is with B. Braun Medical, Ltd.UK to initiate the "Total Pathways Program" program into B. Braun's 26 geographic markets. The program is for pre-habilitation (treatment that happens prior to surgery) and post-operative recovery. This new program will benefit the majority of the 160,000 UK annual knee, hip, or joint replacements patients. According to Keith, BioElectronics is not just trying establishing a brand, but "to establish the process to a standardize care for pre and post-operative pain."
The company is immensely proud of their team for getting their concept through to the National Health Service (NHS) in the UK. In addition to successes here, the company is hoping to utilize their overseas success by applying data to their US-based efforts.
There are some great potential partnerships currently being discussed at BioElectronics, with the closing of a significant deal just on the horizon.
BioElectronics Corp is approaching their upcoming FDA meetings with confidence. "We have the data to make a very strong case for both broader musculoskeletal and post-operative pain relief indications," said Nalepka. "It's an exciting time for the company, and a really cool little product."
For more details on the Total Pathways Program, news about a partnerships, and information about the company's upcoming meetings with the FDA, follow the link below to the full interview.
https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel-3/ ;
About BioElectronics
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
Safe Harbor Statement
Certain statements contained herein are "forward-looking statements," (as defined in the Private Securities Litigation Reform Act of 1995). BioElectronics Corp. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. BioElectronics Corp. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network "Stock Day" Podcast. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Contact Information
Uptick Newswire LLC
Everett Jolly, CEO/Founder
602-441-3474
10000 N. 31st Avenue C307 Phoenix, AZ 85051
info@upticknewswire.com
www.upticknewswire.com
Release #:812-170554-rl-1141231: |
BioElectronics Up-Date |
Dear Fellow Shareholders, This letter is to report on our recent progress in marketing and product development. We have established the following:
We are continuing to solicit new international and domestic sales and marketing partners for distribution and licensing, while strengthening our relationship with existing partners. To aid in this effort we have engaged an accomplished sales and marketing pharmaceutical consultant to assist in introduction and negotiations of sales and marketing partnerships. US Market Clearance ActiPatch®, Musculoskeletal Pain Therapy We are in the process of expanding the US market clearance from relief of osteoarthritis of the knee pain and plantar fasciitis. Our goal is to obtain general clearance for musculoskeletal pain. To achieve this, we have submitted a chronic back pain clinical study to the US FDA as a formal Pre-Sub. The initial meeting with the FDA is tentatively scheduled for May 9th. Prior guidance from the FDA indicated that a third clinical study was required before expanding the current market indications to cover all musculoskeletal pain. We are hopeful that the process will be completed rapidly, however we will not have a good estimate of this market clearance date until the completion of the May 9th meeting. Postoperative Recovery and Pain We have submitted a formal Pre-Sub to the US FDA for guidance in obtaining market clearance for the palliative treatment of postoperative pain and edema. The application is supported by postoperative clinical studies on breast augmentation and caesarean section. Marketing Expansion We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line. Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:
The ActiPatch registry studies report that people buy the device because it is effective, drug-free, has no harmful side effects and overall improves quality of life. We are continually working to solve existing minor issues with the use of ActiPatch. To improve the product, we are introducing custom-design kinesiology tape strips to attach the device to the body. Aside from improving user comfort, this allows us to promote a single multi-purpose box with the added benefit of reducing retail shelf space. We believe this will then allow us to sell the 7-day trial devices from pharmacy shelves. B. Braun UK This is an important development for BioElectronics. B Braun has been using RecoveryRx to improve recovery following joint replacement for many years, although in limited surgeries. However, new advances in day surgery for joint replacement have expanded our opportunity. B. Braun has recently completed a pilot program in the UK evaluating day for joint replacement. The United Kingdom's Group day surgery program for knee and hip replacement patients and is now being implemented on a national basis. Currently there are 80,000 procedures per year involving B Braun. The "fast-track" same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a special wireless technology tablet. Upon hospital discharge, each patient will be given an ActiPatch medical device and a prescription for 6 additional devices to help accelerate recovery and mitigate the postoperative pain. A similar program is in development for spinal surgeries. On an international level, B. Braun's 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services. It is anticipated that B. Braun's German Group will roll out the same day hip and knee replacement program in the next few months.
Smart Insole – Heel Pain Relief We have redesigned the Smart™ Insole plantar fasciitis insole to enhance user comfort. We are awaiting a written License and Supply Agreement for the product. Clinical Research to Expand Market Clearance and Acceptance Allay®, Menstrual Pain Therapy 28% of women are in the menstrual phase of life and 60% have moderate to severe menstrual pain, or 17% of women. Previously our medical devices were classified as high risk class III by the US FDA. While our existing pilot clinical study for menstrual pain reported exceptional results for menstrual pain, to publish a clinical study and obtain US market clearance, we are collaborating with the University Hospital at Birmingham, UK. The researchers here are world renowned thought leaders in women's health and are conducting a double-blind randomized controlled trial to evaluate the efficacy of ActiPatch in reducing menstrual pain (clinicaltrials.gov listing NCT03394547). You can view the existing clinical evidence and our commercials at https://www.myallay.com/ Prevention of Episodic Migraines Headaches Migraines affect 36 million men, women and children in the United States alone. The facts are:
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception; since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attack. There is pilot data that ActiPatch can help mitigate this sensitization, so a study has been completed to determine the efficacy of ActiPatch in preventing chronic, episodic migraines. The data from the study will be analysed in the next few weeks. We believe this data will allow us to work towards developing a product as a migraine therapy and allowing us to obtain market clearance. Postoperative Recovery and Pain Working with our distributor in Lebanon we are conducting a double blind placebo randomized controlled trial on total knee replacement (clinicaltrial.gov NCT03395444). Through our long standing association with B. Braun UK, RecoveryRx has been determined to be a valuable aid in joint replacement surgery. This clinical study will allow us to gain worldwide recognition and allow for expanded marketing and acceptance of the RecoveryRx as a standard of post-operative care following joint replacement. Interstitial Cystitis (Overactive Bladder and Pelvic Pain) This study is a University of Texas, McGovern Medical School sponsored double blind randomized controlled trial. The goal is to determine how well the ActiPatch therapy works in treating patients with interstitial cystitis, bladder pain syndrome and overactive bladder. Interstitial cystitis and bladder pain syndrome are chronic bladder health conditions that greatly affect quality of life. These conditions create intermittent feelings of pain and pressure in the bladder area. The study is expected to recruit 60 women who are urology patients of the University's hospital. At least 35 million Americans have overactive bladder. Lower urinary tract symptoms, urgency, and pelvic pain are common complaints to urologists and primary care physicians. Additional Bioelectronic Product Opportunities As we develop the organizational structure we envision additional opportunities in chronic wounds, neuropathy, hypertensive therapy, etc. Most importantly future growth is not dependent on large capital outlays for research and development. Immediate Sales Growth We anticipate imminent solid sales growth from the following programs:
Thank you for your support. Sincerely,
______________________ |
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK Group to improve care and reduce the UK healthcare cost of its 160,000 annual hip and knee replacement procedures.
The “fast-track” same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a specialized wireless tablet. Each patient will be given an ActiPatch medical device and a prescription for 6 additional ActiPatch devices. A similar program is being implemented for spinal surgeries.
Phil Cleary, Senior Product Group Manager, stated that “our TOTAL Pathway program enhances our commitment to patient safety, post-operative care, as well as significantly reducing healthcare costs and hospital stays.” Treating post-surgical pain requires a multifaceted approach. In trials, ActiPatch was well received and produced positive outcomes. We look forward to making this program a success, in the UK and other countries where B. Braun operates.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
About B. Braun Medical Ltd
B. Braun Medical Ltd, UK, https://www.bbraun.co.uk/ is a member of the B. Braun Group, https://www.bbraun.com/en.html one of the world´s leading healthcare companies. On an international level, B. Braun’s 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services.
Keep in mind partners are happening and licensed ones at that.
The back study will not go in as a new submission, it is included in the knee and ankle submission so this will happen quicker than most would believe. Well actually the back study will be added to the prior submission, I don't want to confuse you
Watch how huge the Co-Branding gets. How many names besides Pain Gear?
Increasing shareholder value=7 components of shareholder value.
• Revenue
• Operating Margin
• Cash Tax Rate
• Incremental Capital Expenditure
• Investment in Working Capital
• Cost of Capital
• Competitive Advantage Period
Within the next 120 days BIEL will have in place-
Full body clearance minus the Migraine, anticipated clearance at a later date based upon the fact that this is a preventative study and the patients must have signs of a migraine coming, this study is a little more complicated.
Licensed partners (Major)
Equity partners
At least 2 huge retail chains
Let’s add on a few more distributors. Why not? Lol
NHS-first week of April, keep in mind not the only week, this is lifetime!
There will be other EU States that will duplicate the NHS and this will be coupled with licenses being sold to partners. What price, how much in royalties will soon be determined.
The August financials will and should be the strength of evidence that a certain person has established a supply chain that will be second to none.
I should mention that sales makeup only one component of the revenue stream, this is where my opinion may differ from the good posters on the BIEL board.
Revenue is the total amount taken in by a business in a set period of time.
This can include royalties, license fees and equity from partners and sales.
BIEL cannot have millions in sales without including the other revenue streams mentioned above.
My revenue forecast including sales may be different than others.
Great rewards will follow in due time. Waiting on the FDA protocol. Which means pre-submission. Guidance, rules and timing will be part of the protocol.(Looks like May-June clearance.)
Migraine clinical results will still be the huge one for the FDA protocol.(August-September clearance on positive results.)
NHS is the first of many EU States getting on board. Pretty good health systems across the pond. Sweden next!
The back pain study will obtain US FDA clearance for relief of musculoskeletal pain. Migraine headaches are not musculoskeletal. Migraines and musculoskeletal pain are both neurological disorders. Two FDA clearances!!!!!!!!!!!!!
SEC-much ado about nothing!
Partners-much ado about something!
12/7/2017 - Try and Tell US Launch, gets a 7 Day ActiPatch to US residents for shipping and handling costs of $4.95
12/7/17 - BIEL closes a deal with ANDA for National Distribution, ANDA has 60,000 commercial customers and is owned by TEVA Pharma, TEVA has extensive business dealings with the NHS
1/4/2018 - ActiPatch gains admission to the UK NHS Drug Tariff as a covered medical device, The NHS is the largest single healthcare delivery organization in the world
1/9/2018 - CARE Pharmacies will be handling the ActiPatch, CARE is an organization of 90 pharmacies in 17 states, CARE will be educating patients on the benefits of drug-free pain relief through Pain Consultations
1/16/2018 - Allay Menstrual Clinical Study is fully enrolled, taking place at the prestigious Birmingham Women's Hospital,an NHS Foundation Hospital
1/22/2018 - BIEL signs deal with Performance Health, 120 outside sales reps, 40 inside reps, KN interview
1/22/2018 - BIEL signs deal with MundiPharma in Australia and 8 other countries, Mundi is associated with Purdue Pharma, KN interview
1/22/2018 - Back Pain Study is complete, BIEL has dialogue ongoing with FDA for submission of Study to expand ActiPatch indications, KN interview
1/22/2018 - Migraine Study will get the full attention of staff now that the Back Study has been completed
1/22/2018 - BIEL in talks with Walmart
1/22/2018 - Meeting scheduled with CVS
This is the last 2 months of activity for BIEL. Any other OTC company would be dancing in the Street if they had accomplished this much in the last year.
The NHS Approval has opened new doors for BIEL and will continue to do so for many years.
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government-funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
References
1 NHS, "NHS Choices," January 2018. [Online].http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
Available: https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pai....
2 Arthritis Research UK, "Muscloskeletal Matters," Keele University, 2009
ActiPatch Cost Assessment Study Used By UK's NHS
http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
This improvement translated into reduced utilization of healthcare services, leading to a 36.8% reduction in health care costs to the NHS over a 3-month period, even after accounting for the cost of the ActiPatch device
Conclusion
Utilizing ActiPatch® as a chronic pain therapy treatment improves patient quality of life, while reducing the economic burden to the NHS.
"Almost half the adult population is living with chronic pain," the Daily Mail reports. A major new review suggests that around 28 million adults in the UK are affected by some type of chronic pain (pain that lasts for more than three months). Read More Link
https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pain/
February 06, 2017 09:05 ET
FREDERICK, MD--(Marketwired - Feb 6, 2017) - BioElectronics Corporation (OTC PINK: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
How to Order an ActiPatch®?
Visit tryactipatch.com to place your order for the ActiPatch® today.
www.tryactipatch.com
BioElectronics Corporation
301-874-4980
info@bielcorp.com
4539 Metropolitan Court
Frederick, MD 21704
ActiPatch Healthcare Utilization Study Link
http://www.harmonyhealth.se/wp-content/uploads/2017/10/ActiPatchHealthcareCostStudy.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |